Design and synthesis of pyrazole derivatives for in vitro screening to protect angiotensin-converting enzyme 2 human cells against COVID-19

Yallappa, Ganesh N; Prasad, Somdutt; Vaidya, Gayatri

doi:10.4103/cmrp.cmrp_10_20

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, pyrazole compounds are potent pharmaceutical structures bearing a wide range of pharmacological and biological properties, including anticancer, [20,21] anti-inflammatory, [22] analgesic, [23] antimicrobial, [24] antitubercular, [25] antiviral, [26,27] antioxidant, [28,29] neuroprotective [30] and antidiabetic [31] activities.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Biological Evaluation, Migratory Inhibition and Docking Study of Indenopyrazolones as Potential Anticancer Agents

Nasab

Han

Shah

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Some bioactive derivatives of indeno[1,2-c]pyrazolones were synthesized through the reaction of phenylhydrazine, different aldehydes and indan-1,2,3-trione at room temperature in acetonitrile. Analytical and spectroscopic studies have confirmed the structural characteristics of the synthesized compounds. In addition, the target compounds were screened for the in-vitro antiproliferative properties against the B16F10 melanoma cancer cell lines by the standard MTT assay. The effect on inflammatory marker cyclooxygenase 2 and matrix metalloproteinase 2, 9 was also checked to determine the anti-inflammatory and anti-cell migratory properties of these compounds. The final compounds were also tested for their tyrosinase inhibitory activity. Among all compounds, screened for anticancer activity, three compounds 4e, 4f and 4h reduced the cell proliferation significantly comparable to that of the positive standard drug erlotinib (IC 50 = 418.9 � 1.54 μM) with IC 50 values ranging from 20.72 -29.35 μM. The compounds 4c -4h decreased the COX-2 expression whereas the MMP 2, 9 expressions were significantly reduced by 4a, 4b and 4h. This was confirmed by molecular docking studies, as 4e, 4f and 4h displayed good interactions with the active site of BRAF protein. The compounds 4b, 4f and 4h exhibited moderate tyrosinase inhibition effect as compared to α-MSH. Collectively, compound 4h can be considered as a candidate for further optimization in the development of anticancer therapies based on the results of biological investigations in this study.

show abstract